성금용 (부산대학교), Puthupparampil Scaria (NIH/NIAID), 임상구 ((주)에스엔비아), 장상수 (부산대학교), Christopher Rowe (NIH/NIAID), Olga Muratova (NIH/NIAID), 엄태준 (부산대학교), 김세민 ((주)에스엔비아), Patrick Duffy (NIH/NIAID), 양승윤 (부산대학교)
초록
내용
Transmission blocking vaccines (TBVs) target the sexual stage of the malaria parasite, and block mosquito-borne transmission. Pre-studied TBVs are administered intramuscularly as adjuvanted injectable formulations, which cause discomfort to patients and require cold storage. Transdermal microneedle (MN) vaccination offers a minimally invasive, potentially self-administered, skin delivery method that can induce immunity without adjuvants. However, precise dose control and ensuring antigen stability during manufacturing remain challenges. Here we developed TBV-coated MN patches using a low-temperature, nanoliter-scale, multiple contact-dispensing process and selectively coated Pfs230 or Pfs230-conjugate antigens on MN tips. In vivo MN vaccination elicited immune responses comparable to intramuscular injection. Unadjuvanted Pfs230 and Pfs230 conjugate MNs achieved titers similar to adjuvanted formulations and retained immunogenicity after 37°C storage.